Form D · Biotechnology

GENEOS Therapeutics, Inc.

Plymouth Meeting, PA · CIK 0001769177

Offering snapshot reported Apr 13, 2023 · SEC filing

Reported sold
$5M
Offering amount: $10M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 31, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 13, 2023Initial$4,999,998No comparison1SEC filing
Mar 28, 2022Initial$17,249,984No comparison9SEC filing
Nov 17, 2020Initial$10,399,998No comparison4SEC filing
Feb 27, 2019Initial$4,499,998No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-478663

Source: Form D, filed Apr 13, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Samuel Broder Director
Casey Cunningham Director
Samuel Dr. Broder Director
James Eadie Director
Ted Fjallman Director
Laurent Humeau Director
Eadie James Director
Joseph Kim Director
J. Joseph Kim Director
Sangwoo Lee Director
Niranjan Y. Sardesai Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
660 West Germantown Pike Suite Ll110
Plymouth Meeting, PA, 19462